Racura Oncology Ltd (ASX:RAC)

Australia · Delayed Price · Currency is AUD

2.590

-0.130 (-4.78%)

Apr 28, 2026, 4:10 PM AEST

155.17% (1Y)

Market Cap	496.98M
Revenue (ttm)	3.48M
Net Income (ttm)	-9.39M
Shares Out	182.71M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	212,660
Average Volume	272,468
Open	2.700
Previous Close	2.720
Day's Range	2.560 - 2.700
52-Week Range	0.990 - 4.900
Beta	0.82
RSI	43.97
Earnings Date	May 28, 2026

About Racura Oncology

Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across various oncology indications with Phase 3 clinical programs in acute myeloid leukaemia, Phase 1a/b program in mutant epidermal growth factor receptor non-s... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2011

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol RAC

Full Company Profile

Financial Performance

In fiscal year 2025, Racura Oncology's revenue was 6.04 million, an increase of 24.96% compared to the previous year's 4.84 million. Losses were -4.79 million, -65.36% less than in 2024.

Financial Statements

News

Racura Oncology Transcript: Status Update

Discovery of EE bisantrene as the sole active isomer led to three new patents, securing up to 25 years of exclusivity and significant commercial potential. RC110 is phase three ready, and partnering efforts focus on Asia-Pacific, with robust protocols ensuring only EE is administered.

7 months ago - Transcripts

Racura Oncology Transcript: AGM 2024

The AGM highlighted major progress in advancing RC220 to clinical trials, board renewal, and a focus on cardioprotection and anti-aging research. Shareholders approved key resolutions, and management emphasized strategic discipline, resource management, and commercialization opportunities.

1 year ago - Transcripts